Bioxodes has appointed Dr Philippe Montyene as chairman of its Board of Directors. The news comes as Bioxodes releases positive interim phase 2a data for its lead candidate, BIOX-101, in the treatment of intracerebral haemorrhage.
“Philippe’s experience and track record in developing new therapies in areas of high unmet medical need will lend invaluable guidance to the company just as new data have confirmed the breakthrough potential of BIOX-101 in treating stroke,” commented Marc Dechamps, CEO of Bioxodes.
Bioxodes confirmed that Monteyne will assume the role with immediate effect. Monteyne currently serves as senior advisor for life sciences at investment firm AltamarCAM Partners, and holds board positions at several biotech companies across Europe. His career includes senior roles at SmithKline Beecham, GSK and Sanofi.
In September, the company announced positive interim results from its BIRCH phase 2a clinical trial of BIOX-101, its lead candidate for stroke. According to interim findings, all patients treated with BIOX-101 experienced a reduction in haematoma volume and showed favourable recovery indicators compared with the standard-of-care control group.
Following these results, Bioxodes is preparing to initiate a registrational, multicentre phase 2b study in patients with intracerebral haemorrhage, with plans to also explore BIOX-101’s potential in acute ischaemic stroke. The company stated that data from this trial could be sufficient to support conditional marketing authorisations in both the US and Europe.
Monteyne commented: “I believe BIOX-101 could revolutionise treatment of stroke, offering a solution for a disorder that, unfortunately, often leads to crippling disabilities or death.
“With no approved therapies for haemorrhagic stroke available today, BIOX-101 promises a unique opportunity to help shape an entirely new market by arming physicians with a drug that may significantly reduce mortality and improve outcomes for this lethal disease.”